SentiBioLogo.jpg
Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights
13 août 2024 16h05 HE | Senti Biosciences, Inc.
– Dose finding ongoing in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML – – Commencement of $8 million grant award from CIRM...
Logo.png
Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial
19 avr. 2024 16h30 HE | Hepion Pharmaceuticals, Inc.
EDISON, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic...
cmi_logo.png
[Latest] Global Liver Cancer Market Size/Share Worth USD 16.3 Billion by 2033 at a 14.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
03 avr. 2024 12h30 HE | Custom Market Insights
Austin, TX, USA, April 03, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Liver Cancer Market Size, Trends and Insights By Type (Hepatocellular Carcinoma...
Logo.png
Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds
16 févr. 2024 08h00 HE | Hepion Pharmaceuticals, Inc.
EDISON, N.J., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial intelligence assisted therapeutic drug...
Elevar Logo for Common Use.png
Elevar Therapeutics to Present at Cantor Fitzgerald Global Healthcare Conference
21 sept. 2023 09h00 HE | Elevar Therapeutics
FORT LEE, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating...
Elevar Logo for Common Use.png
Elevar Therapeutics Joins Benefactors Council of Blue Faery, Leading Hepatocellular Carcinoma Advocacy Group
19 sept. 2023 09h00 HE | Elevar Therapeutics
FORT LEE, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating...
Provider Documenting & Coding Office Visit
The Importance of Accurate Coding and Documentation in Value-Based Care
25 juil. 2023 09h00 HE | CHESS Health Solutions
Winston-Salem, NC, July 25, 2023 (GLOBE NEWSWIRE) -- Much has been written about the gaming of risk coding to drive additional revenue, particularly in the Medicare Advantage (MA) program. From a...
Elevar Logo for Common Use.png
Elevar Therapeutics to Participate in ASCO 2023 and BIO 2023; New Jersey-based Company Secures State License as It Builds Toward Commercialization
01 juin 2023 08h00 HE | Elevar Therapeutics
FORT LEE, N.J., June 01, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating...
Elevar Logo for Common Use.png
Elevar Therapeutics to Present Clinically Supported Poster at AACR 2023 Demonstrating Rivoceranib as a Potent, and Most Selective, TKI for VEGFR-2
16 mars 2023 08h00 HE | Elevar Therapeutics
FORT LEE, N.J., March 16, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who...
Logo.png
Advanced Liver Cancer Drug Pipeline Prospers with an Inrush of Pharma Companies and Emerging Novel Therapies
29 avr. 2021 20h30 HE | DelveInsight Business Research LLP
Los Angeles, USA, April 29, 2021 (GLOBE NEWSWIRE) -- Advanced Liver Cancer Drug Pipeline Prospers with an Inrush of Pharma Companies and Emerging Novel Therapies  A comprehensive analysis of...